This information was published on 2025-01-22T16:12:31 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2475265 |
| (220) |
19 Aug 2024
|
| (300) |
US, 23 Feb 2024, 98/417,765
|
| (511) (510) |
Class 5
Oligonucleotide preparations for the treatment of genetic diseases Class 40 Custom manufacture of biomedical compounds comprised of nucleotide polymers and biomedical compounds comprised of ribonucleic acid polymers all for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders for others; Custom manufacture and processing of human cells for medical purposes for others; Treatment of therapeutic cells for others, namely, pharmacological treatment and processing of therapeutic cells to modify their function for therapeutic purposes Class 42 Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Pharmaceutical research and development incorporating artificial intelligence; Pharmaceutical research and development incorporating genetic learning; Scientific and industrial research; Scientific and industrial research incorporating artificial intelligence; Scientific and industrial research in the field of gene therapies, gene editing, drug discovery and development incorporating genetic learning |
| (540) | CHORD |
| (550) | Word |
| (730) |
Korro Bio, Inc.
|
| (750) |
PHILLIPS ORMONDE FITZPATRICK
|
Find out more about publications on the About page.